Once-Weekly HIV Therapy: A New Era for Adherence
An in-depth look at a new once-weekly HIV treatment strategy that matched daily therapy in a head-to-head trial, with discussion of adherence fatigue, viral suppression, and the importance of diverse clinical data.
The episode also explores the pharmacology behind islatravir and lenacapavir, plus the safety concerns that nearly derailed islatravir before researchers found a lower-dose path forward.
Chapter 1
Breaking the Daily Grind of HIV Care
Dr. James Whitfield
So, we are, we are looking at something really, really striking in the New England Journal of Medicine, Elena. It, it came out July twenty-ninth, twenty twenty-six, and it is honestly a massive shift in how we think about HIV therapy. Imagine going from, you know, swallowing a pill every single day of your life to, well, just once a week. Just once.
Dr. Elena Rodriguez
Right, because even though our current daily pills, like Biktarvy, are incredibly good, I mean, they suppress the virus to undetectable levels, but there is this, this constant clinical issue of adherence fatigue. Taking a pill every single day is a daily reminder of having HIV. It, it brings up privacy issues, disclosure fears, and frankly, there is just zero room for, you know, behavioral flexibility.
Dr. James Whitfield
Exactly. It is a psychological weight. So, this new trial, it is called the ISLEND one trial. It was a randomized, double-blind, active-controlled, noninferiority study across twelve countries. Now, noninferiority, for those who do not live in clinical trial design land, it does not mean we are trying to show the new weekly pill is better. We are trying to prove it is, uh, it is not worse than the current gold standard, Biktarvy, which is B/F/TAF. That is the ethical baseline in HIV research because we already have excellent treatments, so any new option absolutely cannot perform worse.
Dr. Elena Rodriguez
Right, you cannot ethically test a new drug if it might put people at risk of losing viral suppression. And the study cohort itself was, was quite representative, right? They had six hundred and seven participants, all adults with HIV-1 who had been virologically suppressed, meaning their viral load was under fifty copies per mil, for at least six months on daily B/F/TAF.
Dr. James Whitfield
Yes, and the diversity of that cohort is worth highlighting. They had twenty-one percent women, thirty-one percent Black participants, and twenty-six percent Hispanic or Latine participants. That is a big deal because we need trial data that actually reflects the populations most heavily impacted by HIV, not just a homogenous sample group.
Dr. Elena Rodriguez
Absolutely. So, James, what did the actual head-to-head data show after forty-eight weeks?
Dr. James Whitfield
It was, it was remarkably clean. Using the FDA-defined snapshot algorithm, at week forty-eight, zero percent, yes, zero percent of the patients in the once-weekly islatravir-lenacapavir group had viral loads at or above fifty copies per mil. Compare that to the daily B/F/TAF group, where it was zero point three percent, which was exactly one patient. The noninferiority margin was pre-specified at four percentage points, and this result easily, easily cleared that. It showed that weekly dosing can match daily suppression perfectly.
Chapter 2
The Biological Sweet Spot and a Story of Redemption
Dr. Elena Rodriguez
That is just incredible. But, okay, let us talk about the science here, the molecular physics of how these two drugs can actually survive in the body for a whole week. It is a really beautiful synergistic pharmacology. You have got two completely different mechanisms. First, islatravir. It is a first-in-class nucleoside reverse transcriptase translocation inhibitor, or NRTTI. It has these unique structural modifications, a four-prime-ethynyl and a three-prime-hydroxyl group. These allow it to block the physical translocation of reverse transcriptase and act as an immediate chain terminator. And because of that, it remains active as an intracellular triphosphate with an ultra-long half-life of one hundred to one hundred and fifty hours.
Dr. James Whitfield
One hundred to one hundred and fifty hours? That is, that is incredibly long for an oral nucleoside analog.
Dr. Elena Rodriguez
Exactly! And then you pair it with lenacapavir, which is a first-in-class capsid inhibitor. It targets the physical shell of the virus, binding to the interface of capsid subunits. This disrupts multiple stages of the viral life cycle, we are talking nuclear entry, assembly, and core formation. It has this extreme, picomolar potency and an oral half-life of fifteen days. So, when you combine them, you have this powerhouse duo that stays in the system, working on different fronts, for a very long time.
Dr. James Whitfield
But, you know, Elena, islatravir has a bit of a, a dramatic history, right? In late twenty-one, the FDA actually put a complete hold on its development. It was, it was a real scare. The clinical trials had been using higher daily doses, like zero point seventy-five milligrams to two point twenty-five milligrams, and even a monthly dose of one hundred and twenty milligrams. And they started seeing this dose-dependent, though reversible, decline in total lymphocytes and CD4+ T-cell counts. People were terrified the drug was actually damaging patients' immune systems.
Dr. Elena Rodriguez
Right, that was a massive hurdle. How did they find their way out of that?
Dr. James Whitfield
Well, it was a story of redemption, really. The researchers went back to the drawing board and used pharmacokinetic modeling to find the biological sweet spot. They realized that a much lower weekly oral dose of just two milligrams of islatravir could still maintain therapeutic efficacy without causing that lymphocyte drop. And the ISLEND one data proved they got it right. At week forty-eight, the mean change in CD4+ T-cell count was nearly identical between the groups. It was minus ten cells per microliter in the weekly group and minus eighteen cells per microliter in the daily group. No clinical signs of lymphopenia at all.
Dr. Elena Rodriguez
Wow, so they really did thread the needle. But, okay, we have to talk about the practical clinical reality. What happens if a patient actually misses their weekly dose? With a daily pill, if you forget, you usually realize within twenty-four hours and take it. But if you miss a weekly pill, and you do not realize it, you could suddenly have a wide, like, fourteen-day gap in therapy. That seems like a major risk for viral rebound and developing drug resistance.
Dr. James Whitfield
You are hitting on a vital point. Adherence to a weekly regimen has to be strict because the consequences of a miss are much larger. That is why, at least for now, this is strictly a switch therapy. It is for patients who are already fully suppressed and stable, not for someone newly diagnosed who is still trying to get their viral load under control. It is about offering flexibility to those who have proven they can manage their regimen.
Dr. Elena Rodriguez
Mm, that makes complete sense. A reward for stability, but with a need for ongoing vigilance. Well, this is a huge step forward for patient autonomy. Good talking, James, we will see how this rolls out in clinics.
Dr. James Whitfield
Absolutely, Elena. Talk soon.